Research programme: acne therapeutics - Praxis
Latest Information Update: 24 Apr 2007
At a glance
- Originator Praxis Pharmaceuticals
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Acne
Most Recent Events
- 15 Sep 2000 Praxis Pharmaceuticals has filed a provisional patent for the anti-acne compound, which will give them worldwide priority for the compound
- 15 Sep 2000 Findings of an initial clinical trial have been added to the adverse events and Skin Disorders pharmacodynamics section
- 23 Mar 2000 Phase-I clinical trials for Acne in Australia (Topical)